Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults

Journal of Endocrinological Investigation

Volumn 32, Issue 11, 2009, Pages 908-912

  Valle, D ^a   Di Minno, M N D ^b   Palmieri, V ^b   Pezzullo, S ^b   Cirillo, F ^b   Di Somma, C ^b   Di Minno, G ^b,c   Lombardi, G ^b  

^a ELI LILLY   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS   (Italy)

Author keywords

GH deficient adults; IGF I; Insulin; r hGH treatment; Recombinant human growth hormone

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN LIKE GROWTH FACTOR 1 BLOOD LEVEL; LEAN BODY WEIGHT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; RECOMBINANT PROTEINS;

EID: 77649208518     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6434     Document Type: Article

References (29)

1. Binnerts A, Deurenberg P, Swart GR, Wilson JH, Lamberts SWJ. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992, 55: 918-23.
2. De Boer H, Blok GJ, Voerman HJ, De Vries PMJM, Van der Veen EA. Body composition in adult growth hormone deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab 1992, 75: 833-7.
3. Beshyah SA, Freemantle C, Thomas E, et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995, 42: 179-89.
4. De Boer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA. Serum lipid levels in growth hormone deficient men. Metabolism 1994, 43: 199-203.
5. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol 1993, 129: 195-200.
6. Stabler B, Turner JR, Girdler SS, Light KC, Underwood LE. Reactivity to stress and psychological adjustments in adults with pituitary insufficiency. Clin Endocrinol (Oxf) 1992, 36: 467-73.
7. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 1994, 40: 111-6.
8. Whitehead HM, Boreham C, Mcllrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 1992, 36: 45-52.
9. Beshyah SA, Freemantle C, Shahi M, et al. Replacement treatment with biosynthetic growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995, 42: 73-84.
10. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993, 77: 1671-6.
11. Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasburger CJ. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995, 80: 552-7.
12. Rutherford OM, Beshyah SA, Schott J, Watkins Y, Johnston DG. Contractile properties of the quadriceps muscle in growth hormone-deficient hypopituitary adults. Clin Sci 1995, 88: 67-71.
13. Valcavi R, Gaddi O, Zini M, lavicoli M, Mellino U, Portioli I. Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. J Clin Endocrinol Metab 1995, 80: 659-66.
14. Cuneo R, Salomon F, Watts GF, Hesp R, Sonksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993, 42: 1519-23.
15. McGauley G. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Pediatr Scand 1989, 356 (Suppl): 70-2.
16. Mardh G, Lundin K, Borg G, Jonsson B, Lindeberg A. 1994 Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab 1989, (Suppl A): 43-9.
17. Weaver JU, Monson JP, Noonan K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995, 80: 153-9.
18. Smith JC, Evans LM, Wilkinson I, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf) 2002, 56: 493-501.
19. Elhadd TA, Abdu TA, Oxtoby J, et al. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab 2001, 86: 4223-32.
20. Di Minno G, Grandone E, Margaglione M. Clinical relevance of polymorphic markers. Thromb. Haemostas 1997, 78: 462-6.
21. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone treatment on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000, 133: 111-22.
22. Colao A, Di Somma C, Pivonello R, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 2002, 87: 1088-93.
23. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older nondiabetic men. Atherosclerosis 2005, 181: 101-8.
24. Kehely A, Bates PC, Frewer P, et al. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 2002, 87: 1974-9.
25. Johansson JO, Landin K, Johannsson G, Tengbom L, Bengtsson BA. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 1996, 76: 422-8.
26. Blum WF, Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994, 4 (Suppl 1): 11-9.
27. Schubring C, Siebler T, Kratzsch J, et al. Leptin serum concentrations in healthy neonates within the first week of life: relation to insulin and growth hormone levels, skinfold thickness, body mass index and weight. Clin Endocrinol (Oxf) 1999, 51: 199-204.
28. Vaughan DE. Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction. Circulation 2003, 108: 376-7.
29. Kralisch S, Klein J, Lossner U, et al. Plasminogen activator inhibitor-1 expression and secretion are stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes. Mol Cell Endocrinol 2006, 253: 56-62.